CoChat
Sign Up
Cited by 147

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Reduction-oxidation pathways involved in cancer development: a systematic review of literature reviews

Gào, Xīn, Schöttker, Ben·2017·Oncotarget
DOI 10.18632/oncotarget.17128PMC PMC5584299
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.17128

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Flow chart of the systematic literature search
Figure 1 Flow chart of the systematic literature searchCC BY · PubMed Central
Figure 2 Intracellular ROS/RNS sources Abbreviations: ER, endoplasmic reticulum; ETC, Electronic transport chain; LCFAs, Long-chain fatty acids, ROS Reactive Oxygen Species.
Figure 2 Intracellular ROS/RNS sources Abbreviations: ER, endoplasmic reticulum; ETC, Electronic transport chain; LCFAs, Long-chain fatty acids, ROS Reactive Oxygen Species.CC BY · PubMed Central
Figure 3 Oxidative stress-stimulated MAPK signalling pathways Abbreviations: ASK1, Apoptosis signal-regulating kinase 1; BMK1, Big mitogen-activated protein kinase 1; ERK1/2, Extracellular signal-regulated kinase 1/2; ERK5, Extracellular signal-regulated kinase 5; JNK, c-Jun N-terminal kinases; MAPK, Mitogen-activated protein kinase; MAPKK, MAPK kinase; MAPKKK, MAPK kinase kinase; MEK1, MAPK/ERK kinase 1; MEK2, MAPK/ERK kinase 2; MEKK1, MAPK/ERK kinase kinase 1; MEKK2, MAPK/ERK kinase kinase 2; MEKK3, MAPK/ERK kinase kinase 3; MKK3/6, MAPK kinase 3/6; MKK4/7, MAPK kinase 4/7; MLK3, mixed-lineage protein kinase 3; p38, P38 mitogen-activated protein kinase.
Figure 3 Oxidative stress-stimulated MAPK signalling pathways Abbreviations: ASK1, Apoptosis signal-regulating kinase 1; BMK1, Big mitogen-activated protein kinase 1; ERK1/2, Extracellular signal-regulated kinase 1/2; ERK5, Extracellular signal-regulated kinase 5; JNK, c-Jun N-terminal kinases; MAPK, Mitogen-activated protein kinase; MAPKK, MAPK kinase; MAPKKK, MAPK kinase kinase; MEK1, MAPK/ERK kinase 1; MEK2, MAPK/ERK kinase 2; MEKK1, MAPK/ERK kinase kinase 1; MEKK2, MAPK/ERK kinase kinase 2; MEKK3, MAPK/ERK kinase kinase 3; MKK3/6, MAPK kinase 3/6; MKK4/7, MAPK kinase 4/7; MLK3, mixed-lineage protein kinase 3; p38, P38 mitogen-activated protein kinase.CC BY · PubMed Central
Figure 4 Schematic of the PI3K/AKT signalling pathway Abbreviations: AKT, also known as protein kinase B, PKB; FOXO, Forkhead Box O; MMP, Matrix metalloproteinase; mTORC, mammalian Target of Rapamycin Complex; NOX, NADPH Oxidase; PDK1: Phosphoinositide-Dependent Kinase-1; PIP2, Phosphatidylinositol 4,5-bisphosphate; PIP3, Phosphatidylinositol-3,4,5-trisphosphate; PTEN, Phosphatase and tensin homolog; ROS, Reactive Oxygen Species; VEGF, Vascular Endothelial Growth Factor.
Figure 4 Schematic of the PI3K/AKT signalling pathway Abbreviations: AKT, also known as protein kinase B, PKB; FOXO, Forkhead Box O; MMP, Matrix metalloproteinase; mTORC, mammalian Target of Rapamycin Complex; NOX, NADPH Oxidase; PDK1: Phosphoinositide-Dependent Kinase-1; PIP2, Phosphatidylinositol 4,5-bisphosphate; PIP3, Phosphatidylinositol-3,4,5-trisphosphate; PTEN, Phosphatase and tensin homolog; ROS, Reactive Oxygen Species; VEGF, Vascular Endothelial Growth Factor.CC BY · PubMed Central
Figure 5 Schematic of the Keap1-Nrf2-ARE pathway Abbreviations: AKT, also known as protein kinase B, PKB; FOXO, Forkhead Box O; MMP, Matrix metalloproteinase; mTORC, mammalian Target of Rapamycin Complex; NOX, NADPH Oxidase; PDK1: Phosphoinositide-Dependent Kinase-1; PIP2, Phosphatidylinositol 4,5-bisphosphate; PIP3, Phosphatidylinositol-3,4,5-trisphosphate; PTEN, Phosphatase and tensin homolog; ROS, Reactive Oxygen Species; VEGF, Vascular Endothelial Growth Factor.
Figure 5 Schematic of the Keap1-Nrf2-ARE pathway Abbreviations: AKT, also known as protein kinase B, PKB; FOXO, Forkhead Box O; MMP, Matrix metalloproteinase; mTORC, mammalian Target of Rapamycin Complex; NOX, NADPH Oxidase; PDK1: Phosphoinositide-Dependent Kinase-1; PIP2, Phosphatidylinositol 4,5-bisphosphate; PIP3, Phosphatidylinositol-3,4,5-trisphosphate; PTEN, Phosphatase and tensin homolog; ROS, Reactive Oxygen Species; VEGF, Vascular Endothelial Growth Factor.CC BY · PubMed Central
Figure 6 Functions of APE1/Ref-1 Abbreviations: AP-1, Activator protein 1; APE1, Apurinic/apyrimidinic endonuclease; Ref-1, Redox effector factor-1; Egr-1, Early growth response protein 1; Myb, Transcriptional activator Myb; NF-κB, Nuclear factor-κB; PAX, Paired box; P53, Tumor protein p53.
Figure 6 Functions of APE1/Ref-1 Abbreviations: AP-1, Activator protein 1; APE1, Apurinic/apyrimidinic endonuclease; Ref-1, Redox effector factor-1; Egr-1, Early growth response protein 1; Myb, Transcriptional activator Myb; NF-κB, Nuclear factor-κB; PAX, Paired box; P53, Tumor protein p53.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Research works printed but not linked: 91

  1. Lee, 2015, ROS and energy metabolism in cancer cells: alliance for fast growth, Arch Pharm Res, 38, 338, 10.1007/s12272-015-0550-6 · DOI
  2. Jones, 2008, Radical-free biology of oxidative stress, Am J Physiol Cell Physiol, 295, C849, 10.1152/ajpcell.00283.2008 · DOI · Paper page
  3. Telser, 2007, Free radicals and antioxidants in normal physiological functions and human disease, Int J Biochem Cell Biol, 39, 44, 10.1016/j.biocel.2006.07.001 · DOI · Paper page
  4. Roberts, 2009, Molecular regulation of tumor angiogenesis and perfusion via redox signaling, Chem Rev, 109, 3099, 10.1021/cr8005125 · DOI
  5. Finkel, 2014, Cellular mechanisms and physiological consequences of redox-dependent signalling, Nat Rev Mol Cell Biol, 15, 411, 10.1038/nrm3801 · DOI · Paper page
  6. Flohé, 2011, Basic principles and emerging concepts in the redox control of transcription factors, Antioxid Redox Signal, 15, 2335, 10.1089/ars.2010.3534 · DOI
  7. Spitz, 2006, Redox signaling in cancer biology, Antioxid Redox Signal, 8, 1249, 10.1089/ars.2006.8.1249 · DOI
  8. LLeonart, 2013, Oxidative stress and cancer: an overview, Ageing Res Rev, 12, 376, 10.1016/j.arr.2012.10.004 · DOI
  9. Aggarwal, 2010, Oxidative stress, inflammation, and cancer: how are they linked?, Free Radic Biol Med, 49, 1603, 10.1016/j.freeradbiomed.2010.09.006 · DOI · Paper page
  10. Chiarugi, 2012, Oxidative stress, tumor microenvironment, and metabolic reprogramming: a diabolic liaison, Int J Cell Biol, 2012, 762825
  11. Spitz, 2014, Reactive oxygen species in normal and tumor stem cells, Adv Cancer Res, 122, 1, 10.1016/B978-0-12-420117-0.00001-3 · DOI
  12. Wu, 2015, Impact of Oxidative Stress Biomarkers and Carboxymethyllysine (an Advanced Glycation End Product) on Prostate Cancer: A Prospective Study, Clin Genitourin Cancer, 13, e347, 10.1016/j.clgc.2015.04.004 · DOI
  13. Tjønneland, 2013, Association between 8-oxo-7,8-dihydro-2′-deoxyguanosine excretion and risk of postmenopausal breast cancer: nested case-control study, Cancer Epidemiol Biomarkers Prev, 22, 1289, 10.1158/1055-9965.EPI-13-0229 · DOI · Paper page
  14. Gius, 2005, Redox-sensitive signaling factors as a novel molecular targets for cancer therapy, Drug Resist Updat, 8, 322, 10.1016/j.drup.2005.09.002 · DOI
  15. Blasiak, 2014, Role of mitochondria in carcinogenesis, Acta Biochim Pol, 61, 671
  16. Singh, 2010, Mechanisms associated with mitochondrial-generated reactive oxygen species in cancer, Can J Physiol Pharmacol, 88, 204, 10.1139/Y09-135 · DOI
  17. Doroshow, 2014, NADPH oxidases: a perspective on reactive oxygen species production in tumor biology, Antioxid Redox Signal, 20, 2873, 10.1089/ars.2013.5603 · DOI
  18. Cotter, 2014, ROS signalling, NADPH oxidases and cancer, Biochem Soc Trans, 42, 934, 10.1042/BST20140060 · DOI
  19. Dusting, 2011, NADPH oxidase-mediated redox signaling: roles in cellular stress response, stress tolerance, and tissue repair, Pharmacol Rev, 63, 218, 10.1124/pr.110.002980 · DOI
  20. Blair, 2011, Cyclooxygenase- and lipoxygenase-mediated DNA damage, Cancer Metastasis Rev, 30, 437, 10.1007/s10555-011-9298-8 · DOI
  21. Habenicht, 2006, What are cyclooxygenases and lipoxygenases doing in the driver‘s seat of carcinogenesis?, Int J Cancer, 119, 2247, 10.1002/ijc.22153 · DOI
  22. Chlubek, 2013, The effect of reactive oxygen species on the synthesis of prostanoids from arachidonic acid, J Physiol Pharmacol, 64, 409
  23. Bentrem, 2014, Involvement of eicosanoids in the pathogenesis of pancreatic cancer: the roles of cyclooxygenase-2 and 5-lipoxygenase, World J Gastroenterol, 20, 10729, 10.3748/wjg.v20.i31.10729 · DOI
  24. Jain, 2006, The role of nitric oxide in tumour progression, Nat Rev Cancer, 6, 521, 10.1038/nrc1910 · DOI
  25. Nath, 2015, The dual role of iNOS in cancer, Redox Biol, 6, 334, 10.1016/j.redox.2015.08.009 · DOI
  26. Bogdan, 2015, Nitric oxide synthase in innate and adaptive immunity: an update, Trends Immunol, 36, 161, 10.1016/j.it.2015.01.003 · DOI · Paper page
  27. Phang, 2012, Proline dehydrogenase (oxidase) in cancer, Biofactors, 38, 398, 10.1002/biof.1036 · DOI
  28. Franklin, 2006, Reactive oxygen species-induced activation of the MAP kinase signaling pathways, Antioxid Redox Signal, 8, 1775, 10.1089/ars.2006.8.1775 · DOI
  29. Choi, 2015, Compromised MAPK signaling in human diseases: an update, Arch Toxicol, 89, 867, 10.1007/s00204-015-1472-2 · DOI
  30. Klotz, 2005, Phosphoinositide 3-kinase signaling in the cellular response to oxidative stress, Biol Chem, 386, 207
  31. Lee, 2011, Targeting the BMK1 MAP kinase pathway in cancer therapy, Clin Cancer Res, 17, 3527, 10.1158/1078-0432.CCR-10-2504 · DOI
  32. Nebreda, 2009, Signal integration by JNK and p38 MAPK pathways in cancer development, Nat Rev Cancer, 9, 537, 10.1038/nrc2694 · DOI
  33. Ahmadi, 2014, Akt and p53R2, partners that dictate the progression and invasiveness of cancer, DNA Repair (Amst), 22, 24, 10.1016/j.dnarep.2014.07.001 · DOI
  34. Hirsch, 2014, PI3K/AKT signaling pathway and cancer: an updated review, Ann Med, 46, 372, 10.3109/07853890.2014.912836 · DOI
  35. Kaushal, 2014, Oxidative Stress Mechanisms and their Modulation
  36. Regad, 2015, Targeting RTK Signaling Pathways in Cancer, Cancers (Basel), 7, 1758, 10.3390/cancers7030860 · DOI
  37. Studzinski, 2014, Non-receptor protein tyrosine kinases signaling pathways in normal and cancer cells, Crit Rev Clin Lab Sci, 51, 125, 10.3109/10408363.2013.874403 · DOI
  38. Chiarugi, 2005, PTPs versus PTKs: the redox side of the coin, Free Radic Res, 39, 353, 10.1080/10715760400027987 · DOI
  39. Tonks, 2006, Protein tyrosine phosphatases: from genes, to function, to disease, Nat Rev Mol Cell Biol, 7, 833, 10.1038/nrm2039 · DOI
  40. Böhmer, 2006, Protein-tyrosine phosphatases and cancer, Nat Rev Cancer, 6, 307, 10.1038/nrc1837 · DOI
  41. Kazanietz, 2014, Protein kinase C and cancer: what we know and what we do not, Oncogene, 33, 5225, 10.1038/onc.2013.524 · DOI · Paper page
  42. Pinton, 2010, Redox control of protein kinase C: cell- and disease-specific aspects, Antioxid Redox Signal, 13, 1051, 10.1089/ars.2009.2825 · DOI
  43. Chen, 2013, Mst1 and Mst2 kinases: regulations and diseases, Cell Biosci, 3, 31, 10.1186/2045-3701-3-31 · DOI
  44. Levonen, 2014, Role of the Keap1-Nrf2 pathway in cancer, Adv Cancer Res, 122, 281, 10.1016/B978-0-12-420117-0.00008-6 · DOI
  45. Jaiswal, 2013, The transcription factor NF-E2-related factor 2 (Nrf2): a protooncogene?, FASEB J, 27, 414, 10.1096/fj.12-217257 · DOI
  46. Surh, 2014, Oncogenic potential of Nrf2 and its principal target protein heme oxygenase-1, Free Radic Biol Med, 67, 353, 10.1016/j.freeradbiomed.2013.10.819 · DOI
  47. Wang, 2014, Nrf2: bane or blessing in cancer?, J Cancer Res Clin Oncol, 140, 1251, 10.1007/s00432-014-1627-1 · DOI
  48. Chiarugi, 2013, Redox molecular machines involved in tumor progression, Antioxid Redox Signal, 19, 1828, 10.1089/ars.2012.5040 · DOI
  49. Ghosh, 2009, The NF-kappaB family of transcription factors and its regulation, Cold Spring Harb Perspect Biol, 1, a000034
  50. Ichikawa, 2006, Nuclear factor-kappa B: A holy grail in cancer prevention and therapy, Curr Signal Transduct Ther, 1, 25, 10.2174/157436206775269235 · DOI
  51. Kong, 2008, NF-kappaB signaling pathway and its therapeutic implications in human diseases, Int Rev Immunol, 27, 293, 10.1080/08830180802276179 · DOI
  52. Sandaltzopoulos, 2008, Reactive oxygen species and HIF-1 signalling in cancer, Cancer Lett, 266, 12, 10.1016/j.canlet.2008.02.028 · DOI
  53. Monte, 2011, Interaction of p53 with tumor suppressive and oncogenic signaling pathways to control cellular reactive oxygen species production, Antioxid Redox Signal, 15, 1749, 10.1089/ars.2010.3652 · DOI
  54. Pervaiz, 2012, Redox regulation of p53, redox effectors regulated by p53: a subtle balance, Antioxid Redox Signal, 16, 1285, 10.1089/ars.2011.4434 · DOI
  55. Galeotti, Role of MnSOD and p66shc in mitochondrial response to p53, Antioxid Redox Signal.2011;, 15, 1715
  56. Gorgoulis, 2012, PIG3: a novel link between oxidative stress and DNA damage response in cancer, Cancer Lett, 327, 97, 10.1016/j.canlet.2011.12.009 · DOI
  57. Basaga, 2012, Tumor suppressor genes and ROS: complex networks of interactions, Free Radic Biol Med, 52, 7, 10.1016/j.freeradbiomed.2011.09.035 · DOI
  58. Kuphal, 2014, AP-1/c-Jun transcription factors: regulation and function in malignant melanoma, Eur J Cell Biol, 93, 76, 10.1016/j.ejcb.2013.10.003 · DOI
  59. Papavassiliou, 2007, The activator protein-1 transcription factor in respiratory epithelium carcinogenesis, Mol Cancer Res, 5, 109, 10.1158/1541-7786.MCR-06-0311 · DOI
  60. Wagner, 2003, AP-1: a double-edged sword in tumorigenesis, Nat Rev Cancer, 3, 859, 10.1038/nrc1209 · DOI
  61. Maśliński, 2012, Current overview of functions of FoxO proteins, with special regards to cellular homeostasis, cell response to stress, as well as inflammation and aging, Adv Med Sci, 57, 183, 10.2478/v10039-012-0039-1 · DOI
  62. Lam, 2011, Sense and sensitivity: FOXO and ROS in cancer development and treatment, Antioxid Redox Signal, 14, 675, 10.1089/ars.2010.3383 · DOI
  63. Storz, 2011, Forkhead homeobox type O transcription factors in the responses to oxidative stress, Antioxid Redox Signal, 14, 593, 10.1089/ars.2010.3405 · DOI
  64. Gouilleux, 2013, Oxidative metabolism in cancer: A STAT affair?, JAK-STAT, 2, e25764, 10.4161/jkst.25764 · DOI
  65. He, 2009, Wnt/beta-catenin signaling: components, mechanisms, and diseases, Dev Cell, 17, 9, 10.1016/j.devcel.2009.06.016 · DOI · Paper page
  66. Lee, 2013, The way Wnt works: components and mechanism, Growth Factors, 31, 1, 10.3109/08977194.2012.752737 · DOI
  67. Monga, 2011, Role of Wnt/β-catenin signaling in liver metabolism and cancer, Int J Biochem Cell Biol, 43, 1021, 10.1016/j.biocel.2009.09.001 · DOI
  68. Kelley, 2009, The many functions of APE1/Ref-1: not only a DNA repair enzyme, Antioxid Redox Signal, 11, 601, 10.1089/ars.2008.2194 · DOI
  69. Mantha, 2014, APE1/Ref-1 as an emerging therapeutic target for various human diseases: phytochemical modulation of its functions, Exp Mol Med, 46, e106, 10.1038/emm.2014.42 · DOI
  70. Datta, 2012, Alterations in the Smad pathway in human cancers, Front Biosci (Landmark Ed), 17, 1281, 10.2741/3986 · DOI
  71. Matsuda, 2014, Link between PI3K/AKT/PTEN Pathway and NOX Proteinin Diseases, Aging Dis, 5, 203, 10.14336/AD.2014.0500203 · DOI
  72. Gregg, 2013, Lung cancer biomarkers for the assessment of modified risk tobacco products: an oxidative stress perspective, Biomarkers, 18, 183, 10.3109/1354750X.2013.777116 · DOI
  73. Gotteland, 2012, Differential protective effects of quercetin, resveratrol, rutin and epigallocatechin gallate against mitochondrial dysfunction induced by indomethacin in Caco-2 cells, Chem Biol Interact, 195, 199, 10.1016/j.cbi.2011.12.007 · DOI
  74. Ohigashi, 2007, Targeting NOX, INOS and COX-2 in inflammatory cells: chemoprevention using food phytochemicals, Int J Cancer, 121, 2357, 10.1002/ijc.23161 · DOI · Paper page
  75. Aggarwal, 2013, Therapeutic roles of curcumin: lessons learned from clinical trials, AAPS J, 15, 195, 10.1208/s12248-012-9432-8 · DOI
  76. Dennis, 2009, The chemopreventive agent myoinositol inhibits Akt and extracellular signal-regulated kinase in bronchial lesions from heavy smokers, Cancer Prev Res (Phila), 2, 370, 10.1158/1940-6207.CAPR-08-0209 · DOI
  77. Cao, 2015, The role of targeting kinase activity by natural products in cancer chemoprevention and chemotherapy (Review), Oncol Rep, 34, 547, 10.3892/or.2015.4029 · DOI
  78. Dong, 2008, Raf and MEK protein kinases are direct molecular targets for the chemopreventive effect of quercetin, a major flavonol in red wine, Cancer Res, 68, 946, 10.1158/0008-5472.CAN-07-3140 · DOI
  79. Hu, 2015, Discovery of direct inhibitors of Keap1-Nrf2 protein-protein interaction as potential therapeutic and preventive agents, Acta Pharm Sin B, 5, 285, 10.1016/j.apsb.2015.05.008 · DOI
  80. Srivastava, 2011, Green tea catechin, epigallocatechin-3-gallate (EGCG): mechanisms, perspectives and clinical applications, Biochem Pharmacol, 82, 1807, 10.1016/j.bcp.2011.07.093 · DOI
  81. Arbiser, 2012, Targeting NADPH oxidases for the treatment of cancer and inflammation, Cell Mol Life Sci, 69, 2435, 10.1007/s00018-012-1017-2 · DOI
  82. Selemidis, 2014, Understanding the biology of reactive oxygen species and their link to cancer: NADPH oxidases as novel pharmacological targets, Clin Exp Pharmacol Physiol, 41, 533, 10.1111/1440-1681.12238 · DOI
  83. Procopio, 2010, Lipoxygenase inhibitors for cancer prevention: promises and risks, Curr Pharm Des, 16, 725, 10.2174/138161210790883822 · DOI
  84. Reddanna, 2012, Structure and ligand based drug design strategies in the development of novel 5- LOX inhibitors, Curr Med Chem, 19, 3763, 10.2174/092986712801661112 · DOI
  85. Tan, 2015, Cyclooxygenase-2 inhibitors in lung cancer treatment: bench to bed, Eur J Pharmacol, 769, 127, 10.1016/j.ejphar.2015.11.007 · DOI
  86. Munkarah, 2006, The effects of the inhibition of inducible nitric oxide synthase on angiogenesis of epithelial ovarian cancer, Am J Obstet Gynecol, 194, 1110, 10.1016/j.ajog.2005.12.019 · DOI
  87. El-Naggar, 2012, Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy, Expert Opin Ther Targets, 16, 103, 10.1517/14728222.2011.645805 · DOI
  88. Tabernero, 2013, Development of PI3K inhibitors: lessons learned from early clinical trials, Nat Rev Clin Oncol, 10, 143, 10.1038/nrclinonc.2013.10 · DOI
  89. Young, 2013, Transcriptional regulation and its misregulation in disease, Cell, 152, 1237, 10.1016/j.cell.2013.02.014 · DOI
  90. Turkson, 2013, Therapeutic modulators of STAT signalling for human diseases, Nat Rev Drug Discov, 12, 611, 10.1038/nrd4088 · DOI
  91. Vakoc, 2015, Targeting Transcription Factors in Cancer, Trends Cancer, 1, 53, 10.1016/j.trecan.2015.07.001 · DOI · Paper page

Cited by

Sorted by citations

Metadata

Authors
Gào, X., & Schöttker, B.
Venue
Oncotarget
Publisher
Impact Journals, LLC
Published
2017-04-16
Volume
8
Issue
31
Pages
51888-51906
ISSN
1949-2553
DOI
10.18632/oncotarget.17128
PMC
PMC5584299
Cited by
147
References
9
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review